Company intelligence / Profile preview

Neo-Farmacêutica

Anápolis, Goiás, Brazil

Ownership: Private
Employees: ~10000
Development stage: Other

Overview

Neo Química, acquired by Hypera Pharma in 2009, is a national leader in similar products and a major generics manufacturer. Its products are widely distributed in Brazil, with over 120 active molecules and 190 generic presentations, and is recognized for significant market penetration and innovation in the generic segment[3].

Therapeutic areas: EndocrinologyInfectious DiseasesGastroenterologyCardiovascularOtherNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Boehringer Ingelheim (for Buscopan/scopolamine production)Sanofi (OTC and prescription drug portfolio acquisition)

Beyond the preview

Go deeper on Neo-Farmacêutica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neo-Farmacêutica.

Explore the full profile